metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)
versus placebo
	nivolumab plus ipilimumab
	CheckMate 451 (NI ; all population), 2019 Annals of Oncology 30 : ii77–ii80, 2019 NCT02538666	RCT	Extensive stage SCLC (Es-SCLC) - maintenance (M)	nivolumab plus ipilimumab	placebo	patients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy	279 / 275	some concern	inconclusive	inconclusive 8 % decrease in deaths (OS) (PE) suggested 28 % decrease in progression or deaths (PFS)
limited stage SCLC (ls-SCLC) - maintenance (M) limited stage SCLC (ls-SCLC) limited stage SCLC (ls-SCLC) - maintenance (M)
versus no additional treatment
	nivolumab plus ipilimumab
	STIMULI unpublished Ann Oncol. 2022 Jan;33(1):67-79 NCT02046733	RCT	limited stage SCLC (ls-SCLC) - maintenance (M)	nivolumab plus ipilimumab	no treatment added	limited stage SCLC patients who had undergone chemoradiotherapy treated as consolidation treatment	78 / 75	NA	inconclusive	inconclusive 5 % decrease in deaths (OS) (PE) inconclusive 2 % increase in progression or deaths (PFS) (PE) statistically significant 3.1-fold increase in AE (grade 3-4) The immunotherapy combination nivolumab plus ipilimumab did not significantly improve progression-free survival (PFS) or overall survival.